PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: NetCetra, LLC

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Proteonomix, Inc. Agrees to the Sale of its Stem Cell Cosmetic Products with China Companies - Proteonomix, Inc. (prot) announces that it and its subsidiary, Proteoderm, Inc., have entered into a renewable three-year contract with China Biopharma and Sinoquest - Proteonomix.com / NetCetra.com
Proteonomix, Inc. Agrees to the Sale of its Stem Cell Cosmetic Products with China Companies

 

NewswireToday - /newswire/ - Brick, NJ, United States, 2009/02/11 - Proteonomix, Inc. (prot) announces that it and its subsidiary, Proteoderm, Inc., have entered into a renewable three-year contract with China Biopharma and Sinoquest - Proteonomix.com / NetCetra.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Pursuant to the agreement, China Biopharma and Sinoquest will purchase from Proteoderm pre-mixed cosmeceutical materials which they will then bottle, label, package and sell. The products consist of a day cream, a night cream, an under-eye serum, a cleanser and an exfoliant, each containing Proteoderm's unique patent pending natural matrix of bioactive proteins called Matrix NC-138™, for use in anti-aging skin products. The products have been shown to enhance the stimulation of collagen and glandular production, leading to a reduction in lines and wrinkles.Proteonomix is developing a platform for the growth of contaminant-free human embryonic stem (hES) cell lines. This platform may become the backbone of future stem cell research and the Company will make this available to researchers for study. They forecast commercialization of this product in the first quarter of this year.

China Biopharma and Sinoquest shall purchase the material from Proteoderm, and, each month, report sales of units of the product. In addition to the purchase price, they shall pay to Proteoderm a royalty per unit on net sales. The retail price of the units is expected to be approximately $400.
In addition to the license and distribution of Proteoderm's cosmeceuticals, the agreement requires Sinoquest and China Biopharma to purchase shares of Proteonomix' common stock on the open market and to establish a "WOFE," a Wholly Owned Foreign Enterprise, to be owned 60% by Proteoderm and 40% by Sinoquest and China Biopharma. The WOFE will be responsible for the sales and marketing of other Proteoderm products, pursuant to future agreements.

Michael Cohen, CEO of Proteonomix, stated: "We are very pleased to have entered into this agreement with China Biopharma and Sinoquest. We look forward to a long relationship and the establishment of a base of customers in China, Taiwan and Hong Kong. Peter Wang, a principal and the chief executive officer of both Biopharma and Sinoquest, is a successful entrepreneur with a track record of developing companies to explore the burgeoning Chinese market. His last venture was UTStarcom, Inc., a telecommunications company operating in the United States, China and other countries, which trades on NASDAQ. When sold, it had annual gross revenues in excess of $2 billion. We are convinced that Peter can make the distribution of Proteoderm's anti-aging products his next success story."
Peter Wang stated, "Sinoquest and China Biopharma already distribute pharmaceutical products for Merck for products made in Germany and Takeda (takeda.com) (Tokyo Stock Exchange), the largest pharmaceutical company in Japan. Sinoquest and China Biopharma understand the Chinese market and can successfully distribute Proteoderm's unique stem cell-derived anti-aging cosmeceutical. We have begun the design of the packaging and displays and are developing a specialized sales team. We are very excited by our relationship with Proteonomix and Proteoderm and hope it will spell success to all."

About Proteonomix, Inc.
Proteonomix, Inc. (proteonomix.com / proteoderm.com) is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Its research and development program has demonstrated results with more than ten patent applications and multiple products ready to enter their respective markets. Proteonomix has facilities at a number of academic institutions. Its subsidiary, Proteoderm,Inc. has developed a line of anti-aging cosmetics.

"Safe Harbor Statement"
Under the Private Securities Litigation Reform Act of 1995, statements herein relating to the Company's expectations are forward-looking statements. The anticipated results, including the entering into an agreement reflecting the terms of the letter of intent and performance pursuance thereto, may not occur.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: NetCetra, LLC

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Proteonomix, Inc. Agrees to the Sale of its Stem Cell Cosmetic Products with China Companies

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Jim Mahlmann - NetCetra.com 
732-262-7888 mcohen[.]proteonomix.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any NetCetra, LLC securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From NetCetra, LLC / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  Triggr & Bloom





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)